Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women

Thrombosis and Haemostasis

Volumn 85, Issue 4, 2001, Pages 619-625

  Vehkavaara, S ^a   Silveira, A ^a   Hakala Ala Pietila T ^a   Virkamaki A ^a   Hovatta, O ^a   Hamsten, A ^a   Taskinen, M R ^a   Yki Jarvinen H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherosclerosis; Cholesterol; Estradiol; Hemostasis; Triglycerides

Indexed keywords

ANTIGEN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; ESTRADIOL; ESTROFEM; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SELECTIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PARTICLE SIZE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035067690     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615643     Document Type: Article

References (52)

1. Cardiovascular disease in women: Statement for healthcare professionals from the American Cardiovascular disease in women: Statement for healthcare professionals from the American Heart Association
2. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
3. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
4. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
6. Hormone replacement therapy, inflammation, and hemostasis in elderly women
7. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
8. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women
9. Minimization: A new method of assigning patients to treatment and control groups
10. Gerinnungsphysiologische Schellmetode zur Bestimmung des Fibrinogens
11. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes
12. A rapid and simple method for measurement of total protein in very low density lipoprotein by Lowry assay
13. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants
14. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
15. A rapid micromethod for apolipoprotein E phenotyping directly in serum
16. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; Comparison of transdermal and oral treatment regimens
17. Evaluation of radioimmunoassay for estradiol in unextracted serum
18. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels
19. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma
20. Europium as a label in time-resolved immunofluorometric assays
21. Repeated measurements and multiple comparisons in cardiovascular research
22. Continuous, combined hormone replacement: Randomized comparison of transdermal and oral preparations
23. The interconversion of estrone and estradiol by human tissue slices
24. Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women
25. Tissue factor interactions with factor VII: Measurement and clinical significance of factor VIIa in plasma
26. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK hemostasis study
27. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
28. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
29. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
30. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease. Results from the estrogen in women with atherosclerosis study
31. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
32. Coagulation activation following estrogen administration to postmenopausal women
33. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis
34. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation
35. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
36. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
37. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators
38. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
39. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
40. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial
41. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
42. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease
43. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia
44. Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease
45. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
46. Changes in plasma lipoprotein and apoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women
47. Efficacy of transdermal estradiol
48. Biological effects of transdermal estradiol
49. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial
50. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women
51. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women
52. Relationship between serum estradiol levels and the increases in high- density lipoprotein levels in postmenopausal women treated with oral estradiol